NEUPOGEN

Neupogen Adverse Events Reported to the FDA Over Time

How are Neupogen adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Neupogen, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Neupogen is flagged as the suspect drug causing the adverse event.

Most Common Neupogen Adverse Events Reported to the FDA

What are the most common Neupogen adverse events reported to the FDA?

Neutropenia	318 (2.24%)
Febrile Neutropenia	296 (2.08%)
Pyrexia	291 (2.05%)
White Blood Cell Count Decreased	223 (1.57%)
Bone Pain	221 (1.55%)
Drug Ineffective	213 (1.5%)
Dyspnoea	199 (1.4%)
Nausea	175 (1.23%)
Pneumonia	172 (1.21%)
Fatigue	147 (1.03%)
Back Pain	144 (1.01%)
	Show More
Diarrhoea	143 (1.01%)
Anaemia	134 (.94%)
Pain	134 (.94%)
Death	130 (.91%)
Vomiting	122 (.86%)
Infection	119 (.84%)
Platelet Count Decreased	118 (.83%)
Headache	117 (.82%)
Rash	113 (.79%)
Thrombocytopenia	110 (.77%)
Malaise	109 (.77%)
Arthralgia	102 (.72%)
Asthenia	101 (.71%)
Sepsis	99 (.7%)
White Blood Cell Count Increased	95 (.67%)
Weight Decreased	94 (.66%)
Haemoglobin Decreased	92 (.65%)
Pancytopenia	92 (.65%)
Leukopenia	90 (.63%)
Neutrophil Count Decreased	90 (.63%)
Deep Vein Thrombosis	89 (.63%)
Dehydration	89 (.63%)
Dizziness	83 (.58%)
Chest Pain	74 (.52%)
Myalgia	73 (.51%)
Acute Myeloid Leukaemia	71 (.5%)
Confusional State	70 (.49%)
Abdominal Pain	69 (.48%)
Pleural Effusion	69 (.48%)
Hypotension	66 (.46%)
Hypersensitivity	65 (.46%)
Injection Site Pain	65 (.46%)
Pain In Extremity	65 (.46%)
Pulmonary Embolism	65 (.46%)
Chills	60 (.42%)
Cough	60 (.42%)
Septic Shock	60 (.42%)
Myelodysplastic Syndrome	57 (.4%)
Therapeutic Response Decreased	57 (.4%)
Acute Respiratory Distress Syndrome	56 (.39%)
Lung Infiltration	54 (.38%)
Pruritus	54 (.38%)
Alopecia	53 (.37%)
Insomnia	50 (.35%)
Leukocytosis	50 (.35%)
Agranulocytosis	49 (.34%)
General Physical Health Deteriorati...	49 (.34%)
Syncope	47 (.33%)
Delirium	45 (.32%)
Interstitial Lung Disease	45 (.32%)
Hyperhidrosis	44 (.31%)
Stomatitis	44 (.31%)
Petechiae	43 (.3%)
Influenza Like Illness	42 (.3%)
Renal Failure Acute	42 (.3%)
Body Temperature Increased	41 (.29%)
Tachycardia	41 (.29%)
Chest Discomfort	40 (.28%)
Neutropenic Sepsis	40 (.28%)
Oedema Peripheral	39 (.27%)
Respiratory Failure	39 (.27%)
Loss Of Consciousness	38 (.27%)
Myocardial Infarction	38 (.27%)
Renal Failure	38 (.27%)
Dermatitis Allergic	37 (.26%)
Muscle Spasms	37 (.26%)
Splenomegaly	37 (.26%)
Urinary Tract Infection	37 (.26%)
Atrial Fibrillation	36 (.25%)
Hypokalaemia	35 (.25%)
Musculoskeletal Pain	35 (.25%)
Cytokine Storm	34 (.24%)
Mucosal Inflammation	34 (.24%)
Multi-organ Failure	34 (.24%)
Neutrophil Count Increased	33 (.23%)
Pulmonary Fibrosis	33 (.23%)
Urticaria	33 (.23%)
Cellulitis	32 (.22%)
Feeling Abnormal	32 (.22%)
Lung Disorder	32 (.22%)
Depression	31 (.22%)
Erythema	31 (.22%)
Impetigo	31 (.22%)
Abdominal Pain Upper	29 (.2%)
Cardiac Failure	29 (.2%)
Haematuria	28 (.2%)
Proteinuria	28 (.2%)
Red Blood Cell Count Decreased	28 (.2%)
Acute Febrile Neutrophilic Dermatos...	27 (.19%)
Oral Candidiasis	27 (.19%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Neupogen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Neupogen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Neupogen

What are the most common Neupogen adverse events reported to the FDA?

Hematology Investigations	862 (6.06%)
Infections - Pathogen Unspecified	859 (6.04%)
White Blood Cell	852 (5.99%)
Respiratory	543 (3.82%)
Epidermal And Dermal Conditions	473 (3.32%)
Gastrointestinal Signs	473 (3.32%)
Neurological	371 (2.61%)
Therapeutic And Nontherapeutic Effe...	332 (2.33%)
Musculoskeletal And Connective Tiss...	298 (2.09%)
Body Temperature Conditions	296 (2.08%)
Anemias Nonhemolytic And Marrow Dep...	287 (2.02%)
	Show More
Lower Respiratory Tract Disorders	286 (2.01%)
Bone Disorders	272 (1.91%)
Bacterial Infectious	202 (1.42%)
Gastrointestinal Motility And Defec...	188 (1.32%)
Electrolyte And Fluid Balance Condi...	181 (1.27%)
Administration Site Reactions	175 (1.23%)
Leukemias	174 (1.22%)
Cardiac Arrhythmias	167 (1.17%)
Hepatic And Hepatobiliary	162 (1.14%)
Joint	161 (1.13%)
Physical Examination Topics	161 (1.13%)
Headaches	150 (1.05%)
Muscle	148 (1.04%)
Fatal Outcomes	132 (.93%)
Platelet	131 (.92%)
Skin Appendage Conditions	131 (.92%)
Renal Disorders	130 (.91%)
Embolism And Thrombosis	128 (.9%)
Viral Infectious	128 (.9%)
Deliria	123 (.86%)
Fungal Infectious	123 (.86%)
Injuries	114 (.8%)
Allergic Conditions	109 (.77%)
Decreased And Nonspecific Blood Pre...	106 (.75%)
Pleural	98 (.69%)
Medication Errors	93 (.65%)
Oral Soft Tissue Conditions	86 (.6%)
Procedural And Device Related Injur...	84 (.59%)
Urinary Tract Signs	83 (.58%)
Spleen, Lymphatic And Reticulendoth...	81 (.57%)
Hepatobiliary	79 (.56%)
Immune	76 (.53%)
Pulmonary Vascular	75 (.53%)
Coronary Artery	73 (.51%)
Skin Vascular Abnormalities	72 (.51%)
Appetite And General Nutritional	65 (.46%)
Sleep Disorders	61 (.43%)
Heart Failures	59 (.41%)
Gastrointestinal Ulceration And Per...	57 (.4%)
Miscellaneous And Site Unspecified ...	53 (.37%)
Cardiac Disorder Signs	50 (.35%)
Central Nervous System Vascular	49 (.34%)
Angiedema And Urticaria	48 (.34%)
Renal And Urinary Tract Investigati...	48 (.34%)
Enzyme	46 (.32%)
Peritoneal And Retroperitoneal Cond...	46 (.32%)
Microbiology And Serology	45 (.32%)
Vision	45 (.32%)
Anxiety Disorders	44 (.31%)
Metastases	41 (.29%)
Ocular Infections, Irritations And ...	41 (.29%)
Mental Impairment	40 (.28%)
Vascular Hemorrhagic	40 (.28%)
Depressed Mood Disorders	39 (.27%)
Gastrointestinal Hemorrhages	38 (.27%)
Upper Respiratory Tract Disorders	37 (.26%)
Cardiac And Vascular Investigations	36 (.25%)
Glucose Metabolism Disorders	36 (.25%)
Metabolic, Nutritional And Blood Ga...	35 (.25%)
Chemical Injury And Poisoning	34 (.24%)
Myocardial	34 (.24%)
Vascular	34 (.24%)
Hematological And Lymphoid Tissue T...	33 (.23%)
Pericardial	32 (.22%)
Hematopoietic Neoplasms	31 (.22%)
Acid-base	30 (.21%)
Gastrointestinal Inflammatory Condi...	30 (.21%)
Skin And Subcutaneous Tissue	30 (.21%)
Bronchial Disorders	29 (.2%)
Gastrointestinal Stenosis And Obstr...	29 (.2%)
Movement Disorders	29 (.2%)
Thyroid Gland	29 (.2%)
Water, Electrolyte And Mineral	29 (.2%)
Cranial Nerve Disorders	28 (.2%)
Hematological	27 (.19%)
Tongue Conditions	27 (.19%)
Coagulopathies And Bleeding Diathes...	26 (.18%)
Menstrual Cycle And Uterine Bleedin...	26 (.18%)
Eye	25 (.18%)
Vascular Inflammations	25 (.18%)
Lymphomas Non-hodgkins B-cell	24 (.17%)
Protein And Chemistry Analyses	24 (.17%)
Nephropathies	23 (.16%)
Therapeutic Procedures And Supporti...	23 (.16%)
Tissue	23 (.16%)
Investigations, Imaging And Histopa...	22 (.15%)
Respiratory And Mediastinal Neoplas...	22 (.15%)
Obstetric And Gynecological Therape...	21 (.15%)
Seizures	21 (.15%)
Vascular Hypertensive	21 (.15%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Neupogen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Neupogen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.